Cutaneous Metastasis From Prostate Cancer on Posttherapeutic 177 Lu-Prostate-Specific Membrane Antigen Scan.

Authors :: Taghavi M
Ahmadi R
Qutbi M
Source :: Clinical nuclear medicine [Clin Nucl Med] 2024 May 01; Vol. 49 (5), pp. e217-e218. Date of Electronic Publication: 2024 Feb 26.
Publication Year :: 2024
Abstract: Abstract: In this note, we aim to present a patient with a known case of prostate cancer with widespread metastasis to the skeleton and liver who has undergone several cycles of chemoradiotherapy. The patient received 2 doses of 177 Lu-prostate-specific membrane antigen therapy, in which several zones of uptake were detected on the thoracic wall compatible with cutaneous metastatic lesions of prostate cancer.<br />Competing Interests: Conflicts of interest and sources of funding: none declared.<br /> (Copyright © 2024 Wolters Kluwer Health, Inc. All rights reserved.)

Subjects :: Male
Humans
Prostate-Specific Antigen
Dipeptides therapeutic use
Lutetium therapeutic use
Heterocyclic Compounds, 1-Ring therapeutic use
Treatment Outcome
Neoplasm Metastasis
Prostate pathology
Prostatic Neoplasms, Castration-Resistant pathology
Radioisotopes

Full Text Access

Tools